The (murine) type I interferon (IFN) receptor, muIfnar-2, is expressed ubiquitously, and exists as both transmembrane and soluble forms. In the present study we show that the gene encoding muIfnar-2 spans approx. 33 kb on mouse chromosome 16, and consists of nine exons and eight introns. The three mRNA splice variants resulting in one transmembrane (muIfnar2c) and two soluble (muIfnar-2a\2ah) mRNA isoforms are generated by alternative RNA processing of the muIfnar-2 gene. Treatment of a range of murine cell lines with a combination of type I and II IFN showed that the muIfnar-2a and -2c mRNA isoforms were up-regulated independently of each other in L929 fibroblasts and hepa-1c1c7 hepatoma cells, but not in M1 myeloid
INTRODUCTION
The type I interferons (IFNs) are naturally produced regulators of cell growth and differentiation in the haematopoietic and immune systems, and provide the first defence against viral infections [1] . All type I IFNs, which include at least 17 α subtypes, single β, τ, κ and ω isotypes, and the recently identified cytokine, limitin, have similar biological activities [2] [3] [4] and bind to a common cell-surface-receptor complex consisting of two transmembrane proteins, type I IFN receptor (IFNAR)-1 and IFNAR-2 [5] . In addition, IFNs have significant anti-tumour activities and serve specific functions, such as activated T-cell survival factors, activators of natural killer cell cytotoxicity, inhibitors of macrophage and lymphocyte proliferation, and inducers of macrophage differentiation, antibody production and cell-surface-antigen expression [6] .
IFNAR-2 is a member of the class II cytokine receptor family [7] , which also includes the type I and II IFN receptors IFNAR-1, IFNGR1 and IFNGR2, interleukin (IL)-10R1, IL-10R2, IL-22R and tissue factor (a membrane receptor for the coagulation protease factor VII) [8] . These receptors have a common D200 extracellular domain region of approximately 200 amino acids, which has a conserved tertiary structure, cysteine pairs at both N-and C-termini, and can be distinguished from the class I receptors by the absence of the distinctive Trp-Ser-Xaa-Trp-Ser motif present in that class of receptor [9] . We have previously cloned two murine (mu)Ifnar-2 cDNAs in mice corresponding to transmembrane (muIfnar-2c) and soluble (muIfnar-2a) isoforms [10] . The predicted polypeptide sequence of muIfnar-2a was identical with the extracellular domain of the transmembrane Abbreviations used : EST, expressed sequence tag ; GAPDH, glyceraldehyde-3-phosphate dehydrogenase ; GAS, γ-activation sequence ; IFN, interferon ; IL, interleukin ; ISGF3, IFN-stimulated gene factor 3 ; IRF, IFN regulatory factor ; ISRE, IFN-stimulated response element ; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide ; (mu/hu)IFNAR, (murine/human) type I IFN receptor ; poly(A) + , polyadenylated ; RACE, rapid amplification of cDNA ends ; UTR, untranslated region. 1 To whom correspondence should be addressed (e-mail Catherine.Owczarek!med.monash.edu.au).
leukaemia cells. Analysis of the 5h flanking region of muIfnar-2 using promoter-luciferase reporter constructs defined three regulatory regions : a region proximal to exon 1, conferring high basal expression, a distal region conferring inducible expression, and a negative regulatory region between the two. These data represent the first promoter analysis of a type I IFN receptor and, taken together with our previous data demonstrating high expression levels and dual biological functions for muIfnar-2a protein, suggests that the regulation of muIfnar-2 isoform expression may be an important way of modulating type I IFN responses.
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form, except for 11 additional amino acids at the C-terminus. A minor soluble isoform (muIfnar-2ah) of muIfnar-2 has also been cloned [11] , but the biological significance of this transcript is unknown since it was expressed at very low levels relative to the other two transcripts. High levels of a 45 kDa protein, IFN-binding protein, corresponding to soluble muIfnar-2 have been detected in normal mouse serum [12] . We also demonstrated, using transfected cDNAs of either the soluble or transmembrane isoforms of muIfnar-2, that the soluble muIfnar-2 protein was the product of a specific mRNA transcript, and not the consequence of proteolytic cleavage of the transmembrane receptor. Our further studies showed that purified recombinant mufnar-2a competitively inhibited IFN activity in reporter assays, and in antiproliferative and antiviral assays in primary cells. Surprisingly, in primary thymocytes from Ifnar-2 −/− mice, recombinant Ifnar-2a formed a complex with IFN at the cell surface, presumably with Ifnar-1, and transmitted a partial anti-proliferative signal. The potential agonistic and antagonistic activities of soluble muIfnar-2 could thus have a major impact on modulating responses to endogenous and exogenous IFNs. This finding importantly demonstrated a novel aspect of IFN signalling, where the cytoplasmic domain of muIfnar-2c was not essential for a biological effect. Both muIfnar-2 mRNA transcripts were expressed ubiquitously ; however, the mRNA transcript for soluble muIfnar-2a was more abundant than that encoding transmembrane Ifnar-2c in the majority of tissues. The ratio of muIfnar-2a : muIfnar-2c varied from 10 : 1 in the liver and other organs, to 1 : 1 in tissues involved in haemopoiesis, e.g. bone marrow macrophages [10, 12] , suggesting that the two receptor isoforms were regulated independently in a tissuespecific manner, which is likely to have important consequences on the biological actions of IFNs.
Despite the importance of IFNAR isoforms, little information exists to date on the modulation of IFN receptor expression, and no IFNAR promoter has been identified in any species. The structure and chromosomal localization of the muIfnar-2 gene have not yet been described, and relatively little is known about how the specific mRNA isoforms are generated. Information on the molecular mechanism of expression and regulation of muIfnar-2 could provide insights on the function of each isoform in i o, and how each contributes to type I IFN-mediated activity in different cell types.
As a major step towards understanding muIfnar-2 transcriptional regulation, we report here the structure and complete nucleotide sequence of the muIfnar-2 gene, including 8.5 kb of 5h flanking sequence and the characterization of the molecular basis of the alternatively spliced forms of muIfnar-2. We also demonstrate independent regulation of the muIfnar-2 mRNA isoforms in different cell types in response to treatment with type I and II IFN, and identify regions in the promoter of the muIfnar-2 gene that control basal and inducible mRNA expression.
EXPERIMENTAL

Isolation and subcloning of the muIfnar-2 gene
A murine 129SvJ genomic library in λFix II (Stratagene, La Jolla, CA, U.S.A.) was screened with a 303 bp muIfnar-2 cDNA probe spanning nt positions 507-809 of muIfnar-2c cDNA. To obtain further λ genomic clones spanning the extreme 5h end of the muIfnar-2 gene, the same library was subsequently probed with a 588 bp NotI-HindIII fragment corresponding to intron 1 of muIfnar-2 obtained from a bacteriophage clone isolated following the initial library screening. All probes were labelled with [$#P]dCTP using a random primer labelling kit (Roche, Castle Hill, Australia) to specific radioactivities of 6.3i 10) c.p.m.\µg. Bacteriophage plaques were transferred to Hybond-N membranes (Amersham, Little Chalfont, Bucks., U.K.) in duplicate, and hybridized under standard conditions. Filters were then washed under high-stringency conditions [0.5iSSC (where 1iSSC is 0.15 M NaCl\0.015 M sodium citrate)\0.1 % SDS at 65 mC. Positive plaques were identified, and after three further rounds of purification phage DNA was prepared using standard procedures. Phage DNA was digested with restriction enzymes and mapped by Southern blot analysis using specific oligonucleotide probes end-labelled with [$#P]ATP (Amersham) and T4 polynucleotide kinase (Promega). Specific restriction fragments were then subcloned into pBluescript KS (j\k).
Nucleotide sequence analysis of the muIfnar-2 gene
Sequencing of subcloned restriction fragments of genomic clones was performed on plasmid templates using ABI PRISM BigDye Terminator (v3) chemistry and analysed on an ABI 377 DNA sequencer (PE Applied Biosystems, Scoresby, Australia). Exons and intron-exon boundaries were sequenced on both DNA strands ; introns were sequenced on one strand.
5h-and 3h-SMART TM rapid amplification of cDNA ends (RACE)
5h-and 3h-SMART TM RACE-ready cDNA libraries were generated according to the manufacturer's recommendations (Clontech) using 1 µg of polyadenylated [poly(A) + ] mRNA from normal mouse thymus, liver or placenta. 5h-and 3h-RACE AR2-1  5h-GCGGAAGGGTCAGAGGTAAGGCATGCTG-3h  3h RACE  AR2-2  5h-GTGAGGAGGGGGAGAAGCCGCAGGAATA-3h  3h RACE  AR2-3  5h-GTCTCGTGAATCCCCCTCTGGGATG-3h  5h RACE  AR2-4  5h-AAGCTGAGGAGACCGACGGCAGAGA-3h  5h RACE  AR2-5  5h-CCGGAGGCCAAGGGTTCCCA-3h  5h RACE  AR2-6  5h-AGCCAGGCGAAAGGGACGGC-3h  5h RACE  AR2-7  5h-TCTCTAGGCTCGCAGACACCACAAGACA-3h  5h RACE  TE-1  5h-CCACAGCCCCCTTCAATGCCCTGTT-3h  3h RACE  TE-2  5h-GGCAGTCTTTCCACCGACAGCACCA-3h  5h RACE  TE-3  5h-AAAGGCTTCACTGCTTTCCA-3h  5h RACE  TE-4  5h-CCCAGCAGGCTCTGCTTCTTAAAGGCTTC-3h  3h RACE  TE-5  5h-TGTCAGGCACTCAGAAATCAAACGGATGGA-3h  3h RACE  TE-6 5h-GATTCCCCACAGGGTTCACTGGGTCTCC-3h 5h RACE TE-7 5h-AGGTCATACGCGTGCAGTTTGGTGGACA-3h 3h RACE TE-8 5h-TCAGAACTCTCTGCCTTCAGCCCTGCTGT-3h 5h RACE reactions were performed according to the manufacturer's recommendations (Clontech) using 100 units of Advantage 2 polymerase, 0.2 pmol of universal primer mix and 0.2 pmol of genespecific primer (see Table 1 number AF082667) were obtained from http:\\www.ncbi.nlm. nih.gov. Identification of transcribed nucleotide sequences and repeat sequences in the genomic sequence was performed using the NIX application (http:\\menu.hgmp.mrc.ac.uk\menu-bin\Nix\Nix.pl).
Cell culture and IFN treatments
Murine L929 cells were grown in Dulbecco's modified Eagle's medium. Hepa-1c1c7 cells (A.T.C.C.) were cultured in α-minimum essential medium without nucleosides, and M1 murine myeloid leukaemia cells were cultured in RPMI medium. 
Isolation and Northern blot analysis of poly(A) + mRNA
Poly(A) + mRNA from L929 cells, M1 cells and Hepa-1c1c7 cells was prepared essentially as described previously [20] . Northern blots of poly(A) + mRNA were prepared and hybridized as described previously with a range of $#P-labelled probes, including muIfnar-2 cDNA, a 537 bp genomic DNA fragment corresponding to muIfnar-2 intron 1 (accession no. AF367979 ; nt 18027-18563) ; 585 bp or 506 bp cDNA fragments encoding the extracellular and cytoplasmic domains respectively of muIfnar-1 (a gift from Dr G. Uze! , at the Institut de Ge! ne! tique Mole! culaire, CNRS, Montpellier, France), and then washed with 0.2iSSC\0.1 % (w\v) SDS at 65 mC. Blots were finally probed with a $#P-labelled 1.2 kb PstI fragment of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA to normalize the different samples for RNA loading. Filters were exposed to a Phosphor screen, and quantitative analysis was performed using a Fuji BAS 1000 PhosphorImage analyser and MacBAS v2.5 software (Fuji, Melbourne, Australia).
Generation of luciferase reporter constructs and stable transfections
In order to analyse the 5h flanking region of the muIfnar-2 gene for promoters, the following restriction fragments from λ clone 2A-1 (see Figure 1A ) were subcloned into a pGL3-Basic vector (Promega) that also contained the neomycin-resistance gene from pMCIneo inserted into the SalI restriction site for stable cell line generation : 11 kb HindIII-cleaved fragment (nt 539-11638 ; pGL3Neo-H), 3.65 kb SacI-cleaved fragment (nt 6370-10027 ; pGL3Neo-S), 3.1 kb SmaI\HindIII-cleaved fragment (nt 8508-11638 ; pGL3Neo-SH) and 1.7 kb BglII-cleaved fragment (nt 7881-9580 ; pGL3Neo-B) (see accession no. AF367979 for numbering). Before transfection, all constructs were linearized with KpnI. L929 cells were seeded at approx. (1-3)i10& cells\well in a six-well plate in complete growth media, and cultured at 37 mC (in the presence of 5 % CO # ) until 50-80 % confluent. To 100 µl of serum-free media was added 2 µg of linearized DNA, and in another 100 µl of media was added 25 µl of AMINE TM reagent (Invitrogen). The two solutions were mixed gently, and incubated at room temperature for 45 min. The mixture was then added to the cells pre-rinsed with serumfree media, and the volume was made to 2 ml with media. After 18 h incubation, as described above, the media was replaced with complete media and the cells incubated for a further 48 h. At this time, the cells were split 1 : 10 and 1 : 20 into 20 cm# dishes, G418 (or Geneticin ; 600 µg\ml ; Invitrogen) was added and the L929 cells were selected for 2 weeks until single colonies appeared. To confirm the presence of each transfected construct in the clones, PCR was performed using Taq polymerase (Promega), and specific primers on cells were lysed at 55 mC for 1 h, and then at 95 mC for 10 min, in a mixture of 5 µl of 10i Taq polymerase\ 1 µl of 4.5 % (v\v) Nonidet P40\1 µl of 4.5 % (v\v) Tween 20 (ICN) and 0.5 µl of 10 mg\ml Proteinase K (Roche Diagnostics).
Luciferase reporter assays
Aliquots of stably transfected cells (1i10&) were added to each well of a 24-well plate (Falcon, Lincoln Park, NJ, U.S.A.). Following 21 h incubation at 37 mC (5% CO # ) in RPMI or Dulbecco's modified Eagle's medium, the media were removed and to each well was added 1000 units\ml muIFNα4 and 1000 units\ml muIFNγ. For basal promoter analysis, the plates were left untreated for 30 h at 37 mC. The plates were incubated at 37 mC (5% CO # ) for a further 9 h, and then gently washed with PBS. The adherent cells were then lysed for 15 min with 300 µl\well of 5i reporter lysis buffer (Promega) and 20 µl of lysate was analysed on a Lumat LB9501 Luminometer (Berthold, Pforzheim, Germany) for luciferase activity using a luciferase assay kit according to the manufacturer's recommendations (Promega).
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) dye assay for quantification of viable cell numbers
The assessment of viable cell number was performed by an adaptation of the method described by Loveland et al. [21] . To each well of a 24-well plate of adherent cells\media was added 50 µl of 2 mg\ml MTT, and the cells were incubated at 37 mC for 4 h. The media\MTT was then removed, and to the cells was added 150 µl\well DMSO. The absorbance of each well was then read within 30 min at 595 nm using a Bio-Rad 3550 Microplate reader (Bio-Rad).
RESULTS
Structure of the muIfnar-2 gene
In order to determine the molecular origin of the different mRNA splice variants of muIfnar-2, and to study the promoter of the muIfnar-2 gene, we analysed a total of 41 306 bp of mouse genomic DNA (submitted to GenBank2 under accession nos. AF367979 and AF440786) covering all the information contained in the published Ifnar-2 cDNAs [10] (GenBank2 accession nos. AF013486, AF013274, Y09865, Y09813 and NM010509). The muIfnar-2 gene contains 9 exons and 8 introns shown in Figures 1(A) and 1(B). The 5h-flanking sequence of the muIfnar-2 gene lacked a recognizable TATA or CAAT box, making it similar to the 5h-flanking regions of other IFNAR genes, e.g. human (hu)IFNAR-2 [22] and huIFNAR-1 [23] . Exon 1 is approx. 75 % GC-rich, and contains most of the 5h-untranslated region (UTR). Exon 2 contains the initiating codon (ATG) and encodes the rest of the 5h UTR and part of the signal peptide, the remainder of which is encoded by exon 3. The ligand-binding SD100A and SD100B domains of the extracellular domain of muIfnar-2 are encoded by exons 4 and 5, and exons 6 and 7 respectively. Exons 8 and 9 encode the transmembrane and cytoplasmic domains of muIfnar-2c respectively. In addition, exon 9 encodes the nucleotide sequence of muIfnar-2ah produced by alternative splicing (see below), and contains the common 3h UTRs of both muIfnar-2ah and muIfnar-2c. Exon 7h is a 3h continuation of exon 7, and encodes the sequence specific to the muIfnar-2a mRNA isoform, as well as its own 3h UTR. The sizes of the introns range from 0.9 kb (intron 3) to 10.8 kb (intron 1).
The muIfnar-2 genomic sequence was analysed for the presence of repetitive elements, such as B1 and B2 repeats, since these have been implicated in modulating gene expression [24] [25] [26] . As summarized in Table 2 , the most common elements were short interspersed repetitive elements (' SINEs '), long interspersed repetitive elements (' LINEs ') and long terminal repeats (' LTRs '), with frequencies of 9.3 %, 4.47 % and 7.64 % respectively. The GjC content of the muIfnar-2 genomic sequence was also determined (45.65 %), making it similar to the current reported average content for mouse genomic DNA (45.6 %) [27] .
The intron-exon boundaries of the muIfnar-2 gene ( Figure 1B ) conform to the 5h-donor and 3h-acceptor consensus rule GT-AG [28, 29] . The three possible codon disruption phases are present in the muIfnar-2 gene splice junctions ( Figure 1B ). Thus introns 6 and 8 disrupt exons between amino acids (phase 0), introns 1, 2, 3, 5 and 7 interrupt a codon between the first and second nucleotide (phase 1) and intron 4 disrupts a codon between the second and third nucleotide (phase 2). The ' 1-2-1-0-1 ' intron phase pattern between exons 3 and 7, which code for the fibronectin III domains of the extracellular domain of muIfnar-2, is conserved in all cytokine receptor family members with these domains [30] .
Some differences were found between the sequences of the coding exons in the muIfnar-2 gene and the published cDNA Regulation of muIfnar-2 expression sequences. The following differences were observed in the Ifnar-2 genomic sequence compared with the muIfnar-2c cDNA sequence [11] : an A C transversion at nt 698 resulting in a change of lysine glutamate (extracellular domain, SD100B). A C T transition at nt 1046 results in a proline serine transition (exon 8, cytoplasmic domain), but this is not in any Box 1\Box 2 motifs or other known functional domains of the cytoplasmic domain [31] . Two other nucleotide differences (A G, nt 1195 ; and A T, nt 1351) resulted in no amino acid substitutions, and there was a deletion at nt 2156 in the 3h-UTR of muIfnar-2c [11] . Six nucleotide differences (A G, nt 1659 ; C A, nt 2308 ; C G, nt 2362 ; C A, nt 2415 ; T G, nt 2435 ; A G, nt 2465), two nucleotide insertions (G at nt 1921 and C at nt 2428) and four nucleotide deletions (C at nt 1964, C at nt 2011, G at nt 2369 and A at nt 2444) were found in the 3h-UTR of the muIfnar-2c cDNA sequence [10] compared with the genomic sequence. These sequence differences probably represent either polymorphisms or strain differences. In addition, four to eight nucleotides at the 5h-end of the cDNA sequences were not present in the corresponding genomic sequence, and are probably artefacts generated during the construction of the cDNA libraries.
Chromosomal localization of the muIfnar-2 gene
Since the 3h-end of the human IFNAR-2 gene lies less than 0.5 kb from the 5h-end of the human IL-10R2 gene on human chromosome 21q22.1 [32] , we sought to determine whether the same arrangement existed for mouse Il-10r2 gene, previously localized to MMU (mouse) chromosome 16 [33] , and the muIfnar-2 gene. PCR amplification of murine genomic DNA using primers corresponding to exon 9 of muIfnar-2 and exon 1 of muIl-10r2 generated a 2 kb fragment that contained exon 9 of muIfnar-2, exon 1 of muIl-10r2 plus intervening sequence (GenBank2 accession no. AF440786). The muIfnar-2 gene is therefore localized on MMU chromosome 16 at a distance of 61.0 cM and the 3h-end is located approx. 722 bp from the 5h-end of the muIl-10r2 gene. In addition, the synteny of genes for the cytokine receptor cluster (IFNAR-2-IL-10R2-IFNAR-1-IFNGR2) is conserved among human, mouse and chicken species (Figure 2) .
Generation of muIfnar-2 mRNA isoforms by alternative splicing of the muIfnar-2 gene
Comparison of the muIfnar-2 genomic sequence with the cDNA sequences of the muIfnar-2 isoforms indicated that the variant mRNA isoforms of muIfnar-2 arose by alternative splicing of the muIfnar-2 gene. Figure 3(A) shows the pattern of alternative splicing that generates the three muIfnar-2 mRNA isoforms, Ifnar-2a, -2ah and -2c. All three isoforms share exons 1-7. However, muIfnar-2a ignores a splice donor site situated at the exon 7\7h junction, and reads through into exon 7h, which is effectively an extension of exon 7 ( Figure 3A ). Exon 7h also contains a stop codon and polyadenylation recognition sequence specific for the muIfnar-2a transcript. MuIfnar-2ah uses the splice site at the exon 7\7h boundary, but skips exon 8 and splices into exon 9, resulting in a frame shift and a premature stop codon ( Figure 3A ). MuIfnar-2c, which encodes a transmembrane protein, also recognizes the exon 7\7h splice donor site, and splices into exon 8, then exon 9 ( Figure 3A ). This transcript uses a different stop codon to muIfnar-2ah, although both transcripts use the same polyadenylation sequence at the 3h end of exon 9. The pattern of alternative splicing used to generate the mRNA isoforms of muIfnar-2 is different from that used to generate the single soluble and two transmembrane mRNA isoforms of huIFNAR-2 (huIFNAR-2a, -2b and -2c respectively ; Figure  3B ). 5h-and 3h-RACE was performed on expressed sequence tag 1 (EST1 ; GenBank2 accession no. AI451113), located in intron 7 of the Ifnar-2 gene from position 32846 to 33123, using a thymus RACE library and the primers TE-5 to TE-8 (Table 1 ) to see whether it constituted part of another muIfnar-2 alternative mRNA splice form. The 278 bp EST1 did not include any muIfnar-2 coding sequence, had no significant open reading frames, and is of unknown function.
Regulation of muIfnar-2 expression
To determine whether the mRNA expression levels of the muIfnar-2 mRNA isoforms could be regulated by stimuli such as pathogenic organisms or cytokines, murine L929 cells were treated separately with a variety of agents, including muIL-4, muIL-6, muGM-CSF (where ' GM-CSF ' represents granulocyte\ macrophage colony-stimulating factor), muIFNα1, muIFNα4, muIFNγ, lipopolysaccharide (' LPS '), Semliki Forest virus, encephalomyocarditis virus and Sendai virus. Northern blot analysis was then performed on poly(A) + mRNA isolated from these cells using an Ifnar-2 cDNA probe (results not shown). The mRNA transcripts encoding muIfnar-2a and muIfnar-2c were then quantified relative to GAPDH. In all cases, muIfnar-2 expression levels were not significantly affected by these factors in this cell type. Since biological fluids contain mixtures of cytokines, and since IFNα and IFNγ have been reported to act synergistically [34] , we treated the cells with a combination of IFNα and IFNγ. Northern blot analysis of murine L929 cells treated with a combination of 1000 units\ml muIFNα4 and 1000 units\ml muIFNγ for up to 24 h ( Figure 4A) showed that the levels of muIfnar-2a mRNA increased 2-fold after 9 h of treatment (P 0.01), and 3-fold after 24 h (P 0.01) ( Figure  4B ). The levels of muIfnar-2c mRNA achieved a maximal increase of 4.5-fold after 9 h of treatment (P 0.0001), after which they decreased. In contrast, the mRNA levels of the major 4.2 kb muIfnar-1 transcript remained unchanged ( Figures 4A and 4B) . The difference between muIfnar-2a : Gapdh and muIfnar-2c : Gapdh was significant at time points of 3 h (P 0.005) and 9 h (P 0.001).
To investigate whether the changes in muIfnar-2 mRNA expression levels in response to a combination of type I and type II IFN occurred in other murine cell types, the experiment was repeated in murine myeloid leukaemia M1 cells and murine hepatoma 1c1c7 cells. No significant changes in muIfnar-2 isoform mRNA expression levels occurred after treatment of M1 cells with a combination of 1000 units\ml muIFNα4 and 1000 units\mL muIFNγ for 24 h ( Figure 4C) . However, the treatment of hepa-1c1c7 cells with the same factors resulted in a 3-fold increase in muIfnar-2a mRNA expression after 9 h treatment, which then returned to normal after 24 h ( Figure 4D ). The muIfnar-2c mRNA transcript increased 4-fold after 3 h treatment, then returned to normal after 24 h. Levels of muIfnar-1 mRNA expression did not change in either M1 or hepa-1c1c7 cells over time.
Determination of the full-length cDNA sequence of muIfnar-2
In order to examine the promoter of the muIfnar-2 gene, it was first necessary to determine the transcriptional start site. 5h RACE analysis [35, 36] was performed using mouse liver, placenta and thymus SMART TM RACE libraries and the AR2-3, AR2-4, AR2-5 and AR2-6 primers (Table 1) . This generated an additional 116 bp of 5h sequence that was identical and co-linear with the genomic sequence. Sequence analysis of the cloned RACE products identified a major transcriptional start site at nt position 8509 (now defined as j1 when referring to promoter-reporter constructs) and multiple minor sites at nt positions 8520, 8528, 8530 and 8532. Extensive further 5h-RACE experiments, including some in the presence of high-temperature reverse transcriptase (results not shown), failed to yield additional sequence. BLAST analysis was used to identify an EST from GenBank2 in the 5h-flanking region of the muIfnar-2 gene (EST2 ; nt 5366-6098, GenBank2 accession nos. BE691888 and BE623785). 5h-and 3h-RACE was therefore performed out using a mouse-thymus SMART TM RACE library and the TE-1, TE-2, TE-3 and TE-4 primers (Table 1) to determine whether EST2 was part of the muIfnar-2 gene. A total of 1976 bp of contiguous sequence was isolated, corresponding to nt 5797-7772 of the muIfnar-2 genomic sequence. No muIfnar-2 cDNA sequences were present in this sequence, although four repetitive elements were present within the extended EST2 sequence. Analysis of the potential open reading frames encoded by this sequence revealed a putative protein of only 64 amino acids with no homology with any known protein.
5h-RACE analysis from liver and thymus libraries using the AR2-4 and AR2-7 primers (Table 1 ) also produced three PCR products of 1.5, 1.6 and 1.75 kb that corresponded to muIfnar-2 transcripts that read directly into intron 1 from the 5h end of exon 2. These PCR products could represent unspliced transcripts or genomic contamination of the RACE libraries. However, Northern blot analysis of murine spleen poly(A) + mRNA using a 537 bp fragment within this sequence resulted in a weakly hybridizing transcript that was of similar size to the minor 9 kb muIfnar-2 transcript previously reported [10] (results not shown). The significance of this is unknown, but it may represent a minor muIfnar-2 mRNA isoform.
3h-RACE was also performed using a mouse thymus SMART TM RACE library and the primers AR2-1 and AR2-2 ( Table 1) . PCR products of 850, 780 and 650 bp were obtained. Regulation of muIfnar-2 expression Northern blots were sequentially hybridized with muIfnar2c, muIfnar-1 and GAPDH cDNA probes, as described above, and exposed to a Phosphor screen. The radioactivity in each hybridizing band was quantified using a PhosphorImage analyser with MacBAS v2.5 software. Data are expressed as the meanspS.E.M for triplicate experiments, or as the means of duplicate experiments. P values were calculated using Student's t test analysis. (*, P 0.05 ; **, P 0.01 ; ***, P 0.0001).
Sequence analysis of the 850 bp product revealed an extra 215 bp of Ifnar-2ah\-2c cDNA sequence in exon 9 [11] that terminated 117 bp 3h of the genomic sequence. The 780 bp and 650 bp products corresponded to previously identified muIfnar-2 cDNA 3h ends. PCR analysis of genomic DNA indicated that this sequence was co-linear with the genomic sequence (refer to GenBank2 accession number AF440786). The published length of the Ifnar-2a cDNA is 1044 bp, and Ifnar-2ah\2c cDNA is 2708 bp. The additional cDNA sequence generated by 5h-and 3h-RACE resulted in a composite muIfnar-2a cDNA of 1161 bp and a muIfnar-2c cDNA of 3041 bp. Re-examination of the mRNA mobilities of muIfnar-2 transcripts on Northern blots using RNA molecular-size standards indicated that the soluble muIfnar-2a transcript migrated at approx. 1.2 kb, and the muIfnar-2ah and muIfnar-2c transcripts migrated at approximately 3.2 kb, rather than the 1.5 kb and 4.0-4.5 kb reported previously [10, 11] . The lengths of the muIfnar-2 cDNAs are now consistent with their respective mRNA transcript sizes, given the level of resolution on a Northern blot of poly(A) + RNA.
Analysis of the muIfnar-2 regulatory regions
To identify regions of DNA that control basal and inducible muIfnar-2 expression, specific restriction fragments from the 5h-flanking region of the muIfnar-2 gene, exon 1 and part of intron 1 were inserted into a vector containing a luciferase reporter gene 4) . P values for all data points were calculated using Student's t test analysis against V8 (a, P 0.05 ; b, P 0.1 ; c, P 0.0001 ; d, P 0.0005 ; n.s., not significant). MTT assays were also performed to normalize for the cell number.
and a neomycin-resistance gene (pGL3Neo). The numbering of the 5h-flanking sequence is relative to the experimentally determined transcriptional start site at 8509 (j1). Plasmids pGL3Neo-H (nt k7968 to j3131), pGL3Neo-SH (nt k1 to j3131), pGL3Neo-S (nt k2137 to j1520) and pGL3Neo-B (nt k626 to j1073) ( Figure 5A ) were linearized with KpnI, and stably transfected into murine L929 cells. An empty pGL3 vector (pGL3Neo-V) was also transfected. From each transfected construct, 40 clones were isolated and assayed for luciferase activity. Since the majority of clones derived from a particular transfected construct had similar luciferase activities, two to four clones from each construct were selected for further analyses. All four pGL3Neo-SH stable cell lines gave no significant increase in luciferase expression compared with all the pGL3Neo-V clones, suggesting that the 5h region of intron 1 on its own does not regulate basal muIfnar-2 expression ( Figure 5B ) in L929 cells. A significant increase of up to 520-fold (P 0.0001) in luciferase activity was detected in all four pGL3Neo-B clones tested compared with V8 (the highest expressing pGL3Neo-V clone) ( Figure 5B), suggesting that the region at k626 to k1 (positions 7881-8508 of the muIfnar-2 genomic sequence) controlled basal muIfnar-2 expression. One of the pGL3Neo-H stable transfectants (H15) showed an increase of approx. 4.5-fold luciferase activity (P 0.005) compared with V8 ( Figure 5B) . None of the pGL3Neo-S clones showed any significant increase in luciferase activity compared with the vector controls ( Figure 5B ), suggesting that an element that can negatively regulate basal muIfnar-2 expression is located between k2137 to k626.
The region of the Ifnar-2 5h-flanking region responsible for the IFNα\IFNγ induction of Ifnar-2 mRNA expression in L929 cells was investigated next. A representative clone from each stably transfected promoter-reporter construct (S4, SH5, V8, H15 and B22) was treated with a combination of 1000 units\ml muIFNα4 and 1000 units\mL muIFNγ, incubated for 9 h and luciferase activity was assayed. No significant increases in luciferase activity were observed following treatment of the V8 control, S4 or SH5 stable cell lines ( Figure 5C ). However, a 1.9-fold increase in luciferase activity was observed in the B22 cell line (P 0.0005) compared with the V8 control, and a 3.9-fold increase was observed in the H15 cell line (P 0.0001), indicating that there are additional elements in the region k7968 to k2137 controlling inducible Ifnar-2 mRNA expression in L929 cells.
The 5h-flanking region of the muIfnar-2 gene was examined for the presence of transcription-factor-binding sites. Figure 6 shows the position of potential binding sites for the transcription factors Oct-1 (Octamer binding factor-1), the homeodomain factor Nkx-2.5, the CCAAT\enhancer binding protein C\EBPα, AP-1, GATA-1, c-Myb, COUP-TF, c-Rel, IFN regulatory factor (IRF)-1\IRF-2 and the IFN-stimulated response element (ISRE) and γ-activation sequence (GAS) elements. Putative binding sites for the transcriptional repressors COUP-TF and IRF-2 [37] were present in the putative negative regulatory region k2137 to k626. Most significantly, five ISREs and 11 GAS elements [6] were located within the IFN-responsive k7969 to k2137 region ( Figure 5 ), suggesting that one or more of these may be responsible for the observed sensitivity to type I and II IFN.
Comparisons of human and mouse non-coding genomic sequences in regions of conserved synteny have previously been successful in identifying elements regulating gene expression [38] . These regulatory elements can be found in non-coding regions, and have 70 % identity over at least 100 bp. Alignment of the genomic locus containing the huIFNAR-2 gene (GenBank2 accession no. NT011512), including 8.5 kb of 5h-flanking region and mouse genomic sequence containing the muIfnar-2 gene plus Regulation of muIfnar-2 expression
Figure 6 Putative transcription-factor-binding sites in the region proximal to exon 1 of the muIfnar-2 gene
Binding sites for a number of transcription factors (boxed and labelled) predicted by one or more analysis programs in the 5h flanking region of the muIfnar-2 gene proximal to exon 1 (bold uppercase). The Bgl II and Sma I restriction sites used in the generation of promoter-reporter constructs are underlined. The sequence is numbered relative to the major transcriptional start site (shown in italics).
8.5 kb of 5h-flanking sequence, was performed using the programs Dialign2 [19] and AVID (using a window size of 100 bp and a conservation level of 70 %) (N. Bray, A. Fabrikant, J. Lord, J. Schwartz, I. Dubchak and L. Pachter, unpublished work) with similar results obtained. The chicken genomic Ifnar-2 sequence was not analysed, since it only spanned exons 2 to 9. Visualization of only the AVID alignment was performed using VISTA [17, 18] ( Figure 7A ). Only segments with a similarity of 50 % are plotted. As can be seen, exons 1, 2 and 3 were poorly conserved, whilst exons 4 to 9, with the exception of exon 6, were conserved. There were also conserved regions in introns 2, 3, 4 and 6. A 204 bp conserved non-coding sequence with 75 % identity between the human and mouse sequences was located 1.6 kb upstream of the putative transcriptional start site of muIfnar-2 (from k1590 to k1387) in the region that appeared to negatively regulate basal muIfnar-2 expression ( Figure 7B ). In addition to a conserved TopoII consensus sequence, the 204 bp conserved non-coding sequence contained the following conserved transcription factor binding sites : MEF-2, TFIID, NFE1 and GATA-1 ( Figure 7B ).
DISCUSSION
Our previous studies have demonstrated the existence of a soluble, secreted form of the type I IFN receptor chain muIfnar-2, encoded by an alternatively spliced transcript [10] . More recent studies determined that this soluble receptor (muIfnar-2a) was an abundantly expressed protein ( 10 µg\ml) in normal murine serum and other biological fluids, was generated by alternative splicing rather than by proteolytic cleavage of the extracellular domain of transmembrane muIfnar-2c, and had the ability to bind type I IFN [12] . The agonistic and antagonistic actions of soluble muIfnar-2a indicate that it could be a key in i o regulator of the actions of IFNs, and that the modulation of soluble muIfnar-2a expression levels could have profound biological consequences. Other studies demonstrated that the transcript encoding soluble muIfnar-2a was generally more abundantly expressed than that encoding transmembrane muIfnar-2, and that the ratio of soluble (muIfnar-2a) to transmembrane (muIfnar-2c) transcripts varied from 10 : 1 in the liver to 1: 1 in bone-marrow macrophages [12] . This observation suggested independent regulation of the two muIfnar-2 isoforms and potential tissue-specific requirements for soluble muIfnar-2. In order to understand the regulation of muIfnar-2a and muIfnar2c mRNA expression we have characterized the muIfnar-2 gene, determined the molecular basis for the generation of its alternative mRNA splice forms and identified key regulatory elements. We have also extended our initial observations and demonstrated that the levels of the two muIfnar-2 mRNA isoforms could be independently regulated upon stimulation with a combination of type I and II IFN.
The gene encoding huIFNAR-2 has been previously described and, as is the case for muIfnar-2, multiple mRNA isoforms of huIFNAR-2 [22, 39] are generated by alternative splicing (huIFNAR-2a, encoding a soluble form lacking both transmembrane and cytoplasmic domains ; huIFNAR-2b, encoding a truncated non-functional cytoplasmic form ; and huIFNAR-2c, encoding a full-length functional transmembrane form). Although the proteins encoded by these isoforms are similar, the patterns of alternative splicing used to generate the murine and human IFNAR-2 isoforms differ, perhaps due to genetic divergence. To date, however, a murine equivalent of huIFNAR-2b has not been described. In the type I IFN-unresponsive cell line that lacks IFNAR-2c (U5A), signalling could be reconstituted with IFNAR-2c, but not with IFNAR-2b, suggesting that the latter may be a non-functional isoform or dominant negative receptor [22, 40] . However, it is apparent that all but 18 amino acids of the cytoplasmic domain of huIFNAR-2b are encoded by an Alu cassette in its antisense orientation that is incorporated by alternative splicing into the open reading frame of the cytoplasmic domain [41] . Since Alu sequences are not present in rodents, it is likely that this huIFNAR-2 mRNA isoform is specific to primates. The generation of a soluble muIfnar-2 mRNA isoform by splice site suppression appears to be a rare phenomenon among cytokine receptors, which use either exon skipping, such as the soluble murine interleukin-5 receptor α-chain [42] , or soluble-specific exons, such as the soluble leukaemia inhibitory factor (' LIF ') receptor α-chain [43] . However, other genes encoding different classes of receptors have similar alternative splicing patterns, e.g. the rat Fos-responsive gene Fit-1 [44] , the murine Leptin receptor [45] and human CCR5 [46] .
Type II IFN or IFNγ has many overlapping biological activities, but no amino acid sequence similarity with any of the type I IFNs and binds to a different receptor [6] . These overlapping biological functions, such as antiviral and anti-proliferative activities, occur through the common use of transcription factors, such as STAT1 [6] and IRF-9 (p48) [10, 47] , which bind to elements within the promoters of IFN-stimulated genes. In a process known as ' gamma priming ' [34, [48] [49] [50] elements in the promoters of these genes, and enhanced DNAbinding activation of ISGF3 in response to IFNα. This priming or synergy between IFNγ and IFNα might be an important means of ensuring a rapid or amplified response to pathological stimuli.
We therefore determined whether a combination of IFNα and IFNγ might regulate muIfnar-2 expression levels as a means of amplifying a response. Treatment of L929 cells and hepa-1c1c7 cells with a combination of IFNα and IFNγ, but not either cytokine alone, caused the levels of all muIfnar-2 transcripts to be significantly up-regulated over time. Promoter-reporter deletion constructs of the 5h flanking region of Ifnar-2 stably transfected into L929 cells demonstrated that a 600 bp region proximal to the 5h end of exon 1 (regulatory region 1 ; Figure 8a ) conferred high ( 500-fold) basal luciferase activity compared with vector controls, and that a region distal to this contained strong negative regulatory elements (regulatory region 2, Figure 8a) . A 2-fold increase in luciferase activity following treatment of cells containing regulatory region 1 with combined IFNα\γ was also observed, consistent with the increase in muIfnar-2a mRNA after similar treatment. A distal region (regulatory region 3 ; Figure   8a ) was able to induce a greater increase in luciferase activity (approx. 4-fold) after IFNα4 and IFNα\γ treatment, which was also consistent with the increase in muIfnar-2c mRNA levels seen following similar treatment. Given the dominance of the soluble Ifnar-2a mRNA transcript [10, 12] and its reduced ability to be induced by IFNα\γ compared with Ifnar-2c, it is possible that regulatory region 1 may contain an Ifnar-2a-specific promoter, and that regulatory region 3 may contain an Ifnar-2c-specific promoter (Figure 8a ). This may be a situation similar to the bovine growth hormone receptor, whereby different isoform mRNA levels are achieved through the utilization of isoform-specific promoters [51] . In addition, we propose the following model as an explanation for the ability of L929 cells to up-regulate muIfnar-2 mRNA levels only to a combination of IFNα\γ. This model (Figure 8b) utilizes the above process of gamma priming, whereby IFNα or IFNγ cannot up-regulate muIfnar-2 mRNA levels by themselves, but the increased levels of ISGF3 components resulting from IFNγ stimulation allows (in this case the preferential) up-regulation of transmembrane muIfnar-2c mRNA in response to type I IFN (presumably by the binding of ISGF3 to ISRE elements present within regulatory region 3 ; Figure 8b ). The up-regulation of IFNARs on the surface of a cell could then lead to increased biological activity in response to IFNα. Because of the kinetics of muIfnar-2 mRNA isoform induction, it is reasonable to suggest that the later induction of soluble muIfnar-2a mRNA acts as a classical negative feedback loop whereby ligand (type I IFN) induces the expression of an inhibitor of itself. The up-regulation of muIfnar-2 mRNA levels by co-stimulation with IFNα and IFNγ implies further evidence for an additional level of molecular cross-talk between these two cytokines designed to amplify biological responses.
Regulation of cytokine receptor mRNA isoform expression and correlation with disease pathogenesis has been described for several cytokine receptor systems that have soluble and transmembrane forms, including the soluble IL-6 receptor [52] and the soluble leptin receptor [53] . Interestingly, responsiveness of eosinophils to the growth-and-survival factor IL-5 is thought to be controlled by the expression levels of the transmembrane IL-5Rα mRNA isoform relative to the soluble (antagonistic) IL-5Rα alternative splice form. Relatively high levels of transmembrane IL-5Rα mRNA, and hence increased IL-5-responsiveness, has been implicated in the pathogenesis of asthma and eosinophilic diseases, and recent studies have shown that IL-5 ligand can induce a switch towards generating transmembrane IL-5Rα mRNA rather than soluble IL-5Rα mRNA [54] . In contrast with work carried out in mice [10, 12] a comprehensive study of huIFNAR-2 mRNA expression in normal adult tissue has not yet been described, and hence there is limited information on the relative expression levels of IFNAR-2 mRNA transcripts in normal physiological situations. However, recent data have demonstrated synergistic up-regulation of huIFNAR-2 mRNA in liver cells treated with a combination of IFNα and IFNγ [55] . The data presented here demonstrates further that the levels of muIfnar-2a and muIfnar-2c mRNA can be regulated independently, and that this regulation occurs in a temporal and celltype-specific manner. Interestingly, recent studies have suggested that high serum levels of soluble huIFNAR-2 suppressed the effectiveness of IFN therapy in patients with chronic hepatitis C [56] , suggesting that, for the formation of an effective type I IFNmediated response, the antagonistic effects of Ifnar-2a may need to be neutralized by a concomitant increase in Ifnar-2c expression. The studies described here have added a new dimension to analyses of the mouse Ifnar-2 and human IFNAR-2 gene loci, and have increased the number of levels and the complexity that exists for modulating responses to endogenous and exogenous type I IFN via the type I IFN receptor. 
